CATALYST PHARMACEUTICALS, INC. (CPRX) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does CATALYST PHARMACEUTICALS, INC. Do?
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. CATALYST PHARMACEUTICALS, INC. (CPRX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Patrick J. McEnany and employs approximately 80 people, headquartered in CORAL GABLES, Florida. With a market capitalization of $3.0B, CPRX is one of the notable companies in the Healthcare sector.
CATALYST PHARMACEUTICALS, INC. (CPRX) Stock Rating — Hold (April 2026)
As of April 2026, CATALYST PHARMACEUTICALS, INC. receives a Hold rating with a composite score of 46.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.CPRX ranks #854 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CATALYST PHARMACEUTICALS, INC. ranks #59 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
CPRX Stock Price and 52-Week Range
CATALYST PHARMACEUTICALS, INC. (CPRX) currently trades at $24.82. The stock lost $0.78 (3.1%) in the most recent trading session. The 52-week high for CPRX is $26.58, which means the stock is currently trading -6.6% from its annual peak. The 52-week low is $19.05, putting the stock 30.3% above its annual trough. Recent trading volume was 1.3M shares, reflecting moderate market activity.
Is CPRX Overvalued or Undervalued? — Valuation Analysis
CATALYST PHARMACEUTICALS, INC. (CPRX) carries a value factor score of 69/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 14.85x, compared to the Healthcare sector average of 23.63x — a discount of 37%. The price-to-book ratio stands at 3.20x, versus the sector average of 2.75x. The price-to-sales ratio is 5.40x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, CPRX trades at 12.36x EV/EBITDA, versus 6.34x for the sector.
Overall, CPRX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
CATALYST PHARMACEUTICALS, INC. Profitability — ROE, Margins, and Quality Score
CATALYST PHARMACEUTICALS, INC. (CPRX) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 21.5%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 18.6% versus the sector average of -33.1%.
On a margin basis, CATALYST PHARMACEUTICALS, INC. reports gross margins of 85.8%, compared to 71.5% for the sector. The operating margin is 43.6% (sector: -66.1%). Net profit margin stands at 36.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 20.9% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
CPRX Debt, Balance Sheet, and Financial Health
CATALYST PHARMACEUTICALS, INC. has a debt-to-equity ratio of 16.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.08x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $690M.
CPRX has a beta of 0.79, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for CATALYST PHARMACEUTICALS, INC. is 70/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
CATALYST PHARMACEUTICALS, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, CATALYST PHARMACEUTICALS, INC. reported revenue of $565M and earnings per share (EPS) of $1.75. Net income for the quarter was $206M. Gross margin was 85.8%. Operating income came in at $247M.
In FY 2025, CATALYST PHARMACEUTICALS, INC. reported revenue of $589M and earnings per share (EPS) of $1.75. Net income for the quarter was $214M. Gross margin was 85.2%. Revenue grew 19.8% year-over-year compared to FY 2024. Operating income came in at $258M.
In Q3 2025, CATALYST PHARMACEUTICALS, INC. reported revenue of $148M and earnings per share (EPS) of $0.43. Net income for the quarter was $53M. Gross margin was 84.7%. Revenue grew 15.3% year-over-year compared to Q3 2024. Operating income came in at $66M.
In Q2 2025, CATALYST PHARMACEUTICALS, INC. reported revenue of $147M and earnings per share (EPS) of $0.43. Net income for the quarter was $52M. Gross margin was 85.9%. Revenue grew 19.4% year-over-year compared to Q2 2024. Operating income came in at $66M.
Over the past 8 quarters, CATALYST PHARMACEUTICALS, INC. has demonstrated a growth trajectory, with revenue expanding from $123M to $565M. Investors analyzing CPRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
CPRX Dividend Yield and Income Analysis
CATALYST PHARMACEUTICALS, INC. (CPRX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
CPRX Momentum and Technical Analysis Profile
CATALYST PHARMACEUTICALS, INC. (CPRX) has a momentum factor score of 46/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 26/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 5/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
CPRX vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, CATALYST PHARMACEUTICALS, INC. (CPRX) ranks #59 out of 838 stocks based on the Blank Capital composite score. This places CPRX in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing CPRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CPRX vs S&P 500 (SPY) comparison to assess how CATALYST PHARMACEUTICALS, INC. stacks up against the broader market across all factor dimensions.
CPRX Next Earnings Date
No upcoming earnings date has been announced for CATALYST PHARMACEUTICALS, INC. (CPRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy CPRX? — Investment Thesis Summary
CATALYST PHARMACEUTICALS, INC. presents a balanced picture with arguments on both sides. The value score of 69/100 suggests attractive pricing relative to fundamentals. Low volatility (stability score 70/100) reduces downside risk.
In summary, CATALYST PHARMACEUTICALS, INC. (CPRX) earns a Hold rating with a composite score of 46.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CPRX stock.
Related Resources for CPRX Investors
Explore more research and tools: CPRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CPRX head-to-head with peers: CPRX vs AZN, CPRX vs SLGL, CPRX vs VMD.